title: Proteomic systems evaluation of the molecular validity of preclinical psychosis models compared to schizophrenia brain pathology.
abstract: Pharmacological and genetic rodent models of schizophrenia play an important role in the drug discovery pipeline, but quantifying the molecular similarity of such models with the underlying human pathophysiology has proved difficult. We developed a novel systems biology methodology for the direct comparison of anterior prefrontal cortex tissue from four established glutamatergic rodent models and schizophrenia patients, enabling the evaluation of which model displays the greatest similarity to schizophrenia across different pathophysiological characteristics of the disease. Liquid chromatography coupled tandem mass spectrometry (LC-MSE) proteomic profiling was applied comparing healthy and "disease state" in human post-mortem samples and rodent brain tissue samples derived from models based on acute and chronic phencyclidine (PCP) treatment, ketamine treatment or NMDA receptor knockdown. Protein-protein interaction networks were constructed from significant abundance changes and enrichment analyses enabled the identification of five functional domains of the disease such as "development and differentiation", which were represented across all four rodent models and were thus subsequently used for cross-species comparison. Kernel-based machine learning techniques quantified that the chronic PCP model represented schizophrenia brain changes most closely for four of these functional domains. This is the first study aiming to quantify which rodent model recapitulates the neuropathological features of schizophrenia most closely, providing an indication of face validity as well as potential guidance in the refinement of construct and predictive validity. The methodology and findings presented here support recent efforts to overcome translational hurdles of preclinical psychiatric research by associating functional dimensions of behaviour with distinct biological processes.
authors.affiliation: Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, CB2 1QT, United Kingdom.
authors.forename: David A
authors.initials: DA
authors.lastname: Cox
authors.affiliation: Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, CB2 1QT, United Kingdom.
authors.forename: Michael G
authors.initials: MG
authors.lastname: Gottschalk
authors.affiliation: Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, CB2 1QT, United Kingdom.
authors.forename: Hendrik
authors.initials: H
authors.lastname: Wesseling
authors.affiliation: Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, CB2 1QT, United Kingdom.
authors.forename: Agnes
authors.initials: A
authors.lastname: Ernst
authors.affiliation: Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, CB2 1QT, United Kingdom.
authors.forename: Jason D
authors.initials: JD
authors.lastname: Cooper
authors.affiliation: Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, CB2 1QT, United Kingdom. Electronic address: sb209@cam.ac.uk.
authors.forename: Sabine
authors.initials: S
authors.lastname: Bahn
mesh_terms: D000818:Animals; D002853:Chromatography, Liquid; D004195:Disease Models, Animal; D006801:Humans; D007649:Ketamine; D000069550:Machine Learning; D008297:Male; D008822:Mice, Transgenic; D010622:Phencyclidine; D017397:Prefrontal Cortex / Q000378:metabolism* / Q000473:pathology; D060066:Protein Interaction Maps; D040901:Proteomics; D011618:Psychotic Disorders / Q000378:metabolism* / Q000473:pathology; D051381:Rats; D016194:Receptors, N-Methyl-D-Aspartate / Q000172:deficiency / Q000235:genetics; D012559:Schizophrenia / Q000378:metabolism* / Q000473:pathology; D053719:Tandem Mass Spectrometry
chemical_list: C409466:NR1 NMDA receptor; D016194:Receptors, N-Methyl-D-Aspartate; D007649:Ketamine; D010622:Phencyclidine
keywords: Chronic phencyclidine (PCP) rat model; Molecular validity; Proteomics; Psychosis models; Schizophrenia; Systems biology